Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/21/2025

Polymyalgia Rheumatica Management

Diagnosis

  • Polymyalgia rheumatica is characterized by bilateral pain and stiffness in the shoulder girdle, neck, and pelvic girdle, affecting people over 60 years of age, with elevated inflammatory markers and rapid response to low-dose glucocorticoids, commonly presenting with core symptoms such as bilateral pain and stiffness in the shoulder girdle, pain and stiffness in the neck, pain and stiffness in the hip/pelvic girdle, prolonged morning stiffness, and proximal muscle pain without true weakness, according to the Annals of the Rheumatic Diseases and the European League Against Rheumatism 1
  • The diagnosis of polymyalgia rheumatica is primarily clinical, with no single diagnostic test existing, and must be distinguished from conditions that can mimic it, including rheumatoid arthritis, spondyloarthritis, inflammatory myopathies, malignancies, chronic infections, endocrine diseases, fibromyalgia, and polymyositis, according to the Annals of the Rheumatic Diseases 1
  • Required laboratory evaluation for polymyalgia rheumatica includes complete blood count, ESR and CRP, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, and basic biochemistry, as suggested by the Annals of the Rheumatic Diseases 1
  • Both ESR and CRP are important inflammatory markers in the diagnostic workup for PMR 2

Treatment

  • The European League Against Rheumatism recommends an initial glucocorticoid dose of 12.5-25 mg prednisone equivalent daily for patients with polymyalgia rheumatica 1
  • Doses above 30 mg/day are strongly discouraged for patients with polymyalgia rheumatica 1
  • Single daily dosing of GCs is preferred over divided doses, and intramuscular methylprednisolone may be considered as an alternative to oral GCs, with a dose of 120 mg every 3 weeks 1
  • Response to low-dose glucocorticoids (15-20 mg/day of prednisone) is considered confirmatory of the diagnosis, with significant improvement of symptoms within 24-72 hours and normalization of inflammatory markers 1
  • Methotrexate is conditionally recommended for patients at high risk of relapse or glucocorticoid-related adverse events, typically used at doses of 7.5-10 mg/week 1
  • Tofacitinib, an oral Janus kinase inhibitor, may help avoid glucocorticoid-related adverse effects, which affect approximately 50% of polymyalgia rheumatica patients 3
  • Standard dosing of tofacitinib is 5 mg twice daily, with dose adjustments required for patients with moderate to severe renal or hepatic impairment, and those taking potent CYP3A4 inhibitors 4

Monitoring and Prevention

  • Patients with polymyalgia rheumatica should be monitored for symptoms of giant cell arteritis, including headache, jaw claudication, and visual disturbances 1
  • The European League Against Rheumatism recommends monitoring patients every 4-8 weeks in the first year, and every 8-12 weeks in the second year, assessing for GCA symptoms, steroid-related side effects, and comorbidities, with up to 60% of PMR patients experiencing relapse during glucocorticoid tapering 5, 1
  • GCA requires immediate treatment with higher glucocorticoid doses (40-60 mg prednisone) due to the risk of sight loss, and all PMR patients should be monitored for GCA symptoms, according to the European League Against Rheumatism 5
  • Tofacitinib should be avoided during active serious infections, and live vaccines should be avoided during treatment 4
  • Tofacitinib should not be combined with potent immunosuppressants or biologics used for psoriasis, and should be used with caution in pregnancy 4